02 March 2023 | News
First prospective study in the world to assess the efficacy of Mycophenolate in patients requiring hospitalisation because of COVID-19 infection
image credit- shutterstock
A research study of efficacy of Mycophenolate in the treatment of COVID-19 by a team of doctors at Sahyadri Hospitals Deccan Unit was published in 'The Lancet – Regional Health – Southeast Asia'.
The death rate due to COVID-19 infection in patients who received Mycophenolate was significantly less compared to those who did not receive the drug. Also, patients who received Mycophenolate recovered faster from COVID-19 infection and could be discharged from the hospital earlier resulting in a shorter duration of hospital stay. No post Covid lung fibrosis effects were observed. No side effects of Mycophenolate were noted in the study.
Mycophenolate has unique mechanism of action by which it suppresses the multiplication of the virus and reduces the reaction of cytokine storm resulting in better and faster recovery from COVID-19 infection. The drug will be effective against various strains of COVID-19 virus and also against many other viruses. The drug is also relatively inexpensive and easily available in the market.
Mycophenolate is a drug that is used to suppress immunity in certain autoimmune diseases and to prevent rejection after kidney transplantation.
Sahyadri Hospitals is the largest chain of hospitals in Maharashtra with 8 hospitals across three cities of Pune, Nashik and Karad.